Clinical Policy: Cypionate (Depo-Testosterone) and for Injection Reference Number: ERX.NPA.53 Effective Date: 01.01.17 Last Review Date: 11.17 Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description (Depo-Testosterone®) and testosterone enanthate are .

FDA Approved Indication(s) Depo-Testosterone and testosterone enanthate are indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.  Primary (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy  Hypogonadotropic hypogonadism (congenital or acquired) - or luteinizing hormone- releasing hormone deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation

Limitation(s) of use: Safety and efficacy of Depo-Testosterone and testosterone enanthate injection in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established.

Additionally, testosterone enanthate is indicated for:  Treatment of in carefully selected males  Women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal

Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Depo-Testosterone and testosterone enanthate are medically necessary when the following criteria are met:

I. Initial Approval Criteria A. Hypogonadism (must meet all): 1. Diagnosis of primary hypogonadism or hypogonadotropic hypogonadism; 2. Documentation of serum testosterone level < 300 ng/dL on at least two separate days within the last 6 months. Approval duration: 12 months

B. Delayed Puberty (must meet all): 1. Diagnosis of delayed puberty; 2. Prescribed by or in consultation with an endocrinologist. Approval duration: 6 months

C. (must meet all): 1. Diagnosis of breast cancer; 2. Prescribed by or in consultation with an oncologist; 3. Disease is metastatic. Approval duration: 12 months

D. Other diagnoses/indications

Page 1 of 3 CLINICAL POLICY Testosterone Cypionate/Enanthate for Injection

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy A. Hypogonadism and Breast Cancer (must meet all): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria; 2. Member is responding positively to therapy. Approval duration: 12 months

B. Delayed Puberty (must meet all): 1. Member must meet initial approval criteria for reauthorization. Approval duration: N/A

C. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy. Approval duration: Duration of request or 12 months (whichever is less); or 2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized: A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents; B. Age-related hypogonadism or late-onset hypogonadism.

IV. Appendices/General Information Appendix A: Abbreviation/Acronym Key FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives N/A

V. Dosage and Administration Drug Name Indication Dosing Regimen Maximum Dose Testosterone cypionate Male hypogonadism 50 to 400 mg IM every 2 to 4 Dosage is (Depo-Testosterone) weeks adjusted Testosterone enanthate Male hypogonadism 50 to 400 mg IM every 2 to 4 according to the weeks patient's Males with delayed 50 to 200 mg IM every 2 to 4 response to puberty weeks for a limited duration, treatment and for example, 4 to 6 months the appearance Palliation of 200 to 400 mg IM every 2 to of adverse inoperable mammary 4 weeks reactions cancer in women

VI. Product Availability Drug Name Availability Testosterone cypionate (Depo-Testosterone) Injection (10 mL multiple dose vial): 200 mg/mL Testosterone enanthate Injection (5 mL multiple dose vial): 200 mg/mL

Page 2 of 3 CLINICAL POLICY Testosterone Cypionate/Enanthate for Injection

VII. References 1. Testosterone enanthate Prescribing Information. Corona, CA: Watson Pharma, Inc.; June 2015. Available at: https://dailymed.nlm.nih.gov/dailymed/. Accessed September 12, 2017 2. Depo-Testosterone Prescribing Information. New York, NY: Pharmacia & Upjohn Co.; February 2017. Available at: https://dailymed.nlm.nih.gov/dailymed/. Accessed September 12, 2017. 3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: http://www.clinicalpharmacology-ip.com/.

Reviews, Revisions, and Approvals Date P&T Approval Date Policy created. 12.16 01.17 4Q17 Annual Review 09.12.17 11.17 Converted to new template. Hypogonadism: Specified concentration of testosterone that is below the normal range within the last 6 months. Increased approval duration from 6 to 12 months. Delayed puberty: Added prescriber specialty. Removed male gender restriction to avoid gender discrimination. Removed requirement that request is for enanthate since specialist is involved in care. Added continued therapy section to clarify that member must meet initial approval criteria for reauthorization. Breast Cancer: Removed gender restriction. Added prescriber specialty as judgment concerning therapy should be made by an oncologist with expertise in this field per PI. Removed requirement that request is for enanthate since specialist is involved in care. Added metastatic disease per PI. Increased approval duration from 6 to 12 months. Added age-related hypogonadism or late-onset hypogonadism as indications for which coverage is not authorized as safety and efficacy have not been established per PI.

Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.

Page 3 of 3